Dec 4 (Reuters) - The Centers for Medicare & Medicaid Services on Wednesday said it had entered into agreements with Vertex Pharmaceuticals VRTX.O and bluebird bio BLUE.O to help increase patient access to their gene therapies.
The so-called "outcomes-based agreements" will tie payments to whether the therapy improves health outcomes for patients who receive these drugs and are enrolled in government-backed Medicaid insurance plans.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Maju Samuel)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。